Michail_Petrov-96 As the American Diabetes Association's 84th Scientific Sessions wraps up Monday, two key players in the diabetes treatment space are trading down. In early afternoon trading, Tandem Diabetes Care ( NASDAQ: TNDM ) is down ~6% , while DexCom ( NASDAQ: DXCM ) is off ~4% . Both companies made presentations at the conference.
Tandem released results from a quality of life survey from users of its Tandem Mobi insulin pump. Meanwhile, DexCom released additional data on the benefits of its continuous glucose monitors . In addition, Insulet ( PODD ) released positive results from the pivotal SECURE-T2D trial on the Omnipod 5 insulin delivery system.
Shares are trading flat. In a note, Oppenheimer noted that the planned August launch of DexCom's over-the-counter CGM , Stelo, should be a driver for the company. The Tandem and DexCom declines could be a reaction to positive phase 2 data released this morning on Altimmune's ( ALT ) weight loss candidate, pemvidutide.
More on DexCom, Tandem Diabetes Tandem Diabetes Care: Recent Rally Fully Deserved, Likely More Upside Here Dexcom: Positive Catalysts Ahead To Support Growth DexCom: Attractive Discount After Strong Earnings Results Tandem Diabetes Care names Jean-Claude Kyrillos as COO DexCom expands AID partnership into the Netherlands.